Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* • more than twenty years of age~  * patients should have 4 or more items positive among the 10 items of the DN4 questionnaire.~ * persistence of neuropathic pain for more than three months or remission and recurrence of neuropathic pain for more than six months~ * a pain score of 4 or more on the numeric rating scale~Exclusion Criteria:~* • neuropathic pain caused by confounding factors other than diabetic neuropathic pain~  * contraindicated for botulinum toxin type A~ * a change in pain medication one month prior to study enrollment~ * a condition involving neuromuscular junction (Ex. Eaton Lambert disease, myasthenia gravis)~ * person who received botulinum toxin type A within three months prior to study enrollment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal saline (Type: PLACEBO_COMPARATOR): Normal saline
- Botulinum toxin type A 50U (Type: ACTIVE_COMPARATOR): Botulinum toxin 50U
- Botulinum toxin type A 100U (Type: ACTIVE_COMPARATOR): Botulinum toxin 100U

Based on this trial design, predict the completion outcome and termination type (if applicable).